Several clinical studies indicated that pancreatic cancer patients with high hENT1 expression in primary tumors have a longer survival after gemcitabine-based chemotherapy than patients with low hENT1 expression (14–17). Here, SLC29A1 is linked to pancreatic neoplasm.